Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04276870 · ClinicalTrials.gov registry record · Phase 2

Orphan Indications for CD19 Redirected Autologous T Cells

A Phase 2 study of Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL and Infants With Very High Risk KMT2A B-ALL, sponsored by Stephan Grupp MD PhD.

Recruiting
Registry status
Phase 2
Development phase
133
Enrollment target
1
Study location

NCT04276870 is a Phase 2 study of Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL and Infants With Very High Risk KMT2A B-ALL that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 133 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04276870, a Phase 2 study of Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL and Infants With Very High Risk KMT2A B-ALL, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.

RECRUITING
Registry status
Phase 2
Development phase
133 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D).

Interventions

  • BIOLOGICAL Murine CART19

Study Locations (1)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 133 participants
Start Date 2020-03-12
Est. Completion 2037-03-10
Phase Phase 2

Sponsor

Stephan Grupp MD PhD

8 total trials

What the Registry Record Tells You About NCT04276870

The ClinicalTrials.gov registry entry for NCT04276870 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephan Grupp MD PhD, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL appearing as the primary indexed condition, and to 1 intervention - of which Murine CART19 is the first listed.

NCT04276870 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04276870 about?

NCT04276870 is a clinical study titled "Orphan Indications for CD19 Redirected Autologous T Cells". This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did n...

What is the current status of trial NCT04276870?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2020-03-12. Estimated completion is 2037-03-10.

What conditions does trial NCT04276870 study?

This clinical trial studies the following conditions: Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation.

What interventions are being tested in trial NCT04276870?

The interventions under investigation include: Murine CART19 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04276870?

This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04276870 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.